US humanoid robot production could hit 400,000 by 2030 as deployment ramps, J.P. Morgan says

By Reuters News

- Humanoid robot production in the US will hit 300,000-400,000 units by 2030 and about 1.5 million units by 2035, J.P. Morgan said on Thursday, as the industry shifts from demonstrations to commercial deployment.

Labor shortages, improving economics and rising production capacity are boosting humanoid adoption in manufacturing, logistics and warehousing, as businesses look to automate repetitive tasks.

  • The Trump administration's finding that imported robotics and industrial machinery pose national security risks could lead to tariffs or other measures to boost domestic production, J.P. Morgan said

  • Humanoid deployment is constrained by hardware, AI training data and compute, and production capacity, with most US manufacturers outside Tesla TSLA.O targeting 10,000-30,000 units annually

  • The brokerage estimates humanoid robot costs are nearing parity with labor costs, while multi-shift deployment could generate about $100,000 in annual savings per customer

  • "Near-term progress remains supply constrained, with a few binding bottlenecks: hands, actuators, the brain, and production capacity," the brokerage said

  • Component suppliers offer the biggest near-term opportunity, J.P. Morgan said, adding it expects the market for key parts such as actuators, motors and vision systems to approach $30 billion by 2035

  • Among US humanoid makers, J.P. Morgan highlights Tesla's TSLA.O Optimus, Agility Robotics' AGLT.O Digit, Boston Dynamics' Atlas, Figure AI's Figure robots, and Apptronik's Apollo as key players

  • J.P. Morgan favors component suppliers including Timken TKR.N, Robotis 108490.KQ, Leader Drive688017.SS , Orbbec 688322.SS, and Cognex CGNX.O

  • The brokerage expects value creation over time to shift toward robot makers and platform integrators

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.